Remibrutinib results in significant improvement in patients still symptomatic after second-generation H1-antihistamine treatment.

Longtime Southcentral Alaska beekeepers say that for decades, many have killed their insects each summer. But for some, ...

Morgan Stanley backs Celldex Therapeutics for growth with barzolvolimab's market-leading potential in chronic urticaria. Read ...

A recent survey found an average loss of 62% of bee colonies among commercial operations in less than a year. Causes and ...

Most people associate sneezing, runny nose, coughing, and hives as a reaction to some types of allergens. Surprisingly, to ...

Living with a cat or dog a person is allergic to can be difficult. But an allergist says there are ways to get relief, and ...

Novartis is just months away from filing for approval of oral BTK inhibitor remibrutinib as a treatment for chronic spontaneous urticaria – also known as chronic hives – after reporting long ...

Almirall, a global pharmaceutical company dedicated to medical dermatology hosts the 16th edition of Skin Academy, a premier conference for healthcare professionals in the field of dermatology. This ...

Symptoms that warrant immediate emergency care, from chest pain to severe allergic reactions, and when urgent care or ...

Novartis' big-selling IgE inhibitor Xolair has been a mainstay of treatment for refractory chronic spontaneous urticaria (CSU) for many years, but its efforts to find a successor have seen some ...

Received European Commission approval for GOHIBIC® (vilobelimab) for the treatment of SARS-CoV-2-induced acute respiratory distress syndrome ...

Almirall has announced that it will be hosting the 16th edition of its Skin Academy, a conference that encourages ...